Presentations
Realising the Value of Medical Research: Health and Economic Benefits
20 March 2013
OHE’s Jon Sussex is spoke today on the value of medical research at the 2013 BioWales conference, one of the UK’s largest life sciences conferences. Celebrating…
Reasons for Discontinuation of R&D Projects: Lead and Follow-on Indications
12 March 2013
The reasons for discontinuation of R&D projects in the biopharmaceutical industry are often a matter of conjecture. In a recent presentation to the 25th Annual EuroMeeting…
Review of Plans for Refining Patient-Reported Outcomes Measures
19 February 2013
At a recent meeting of the Pharmaceutical Onology Initiative’s (POI) HTA group, OHE’s Nancy Devlin provided an overview of the EuroQol Group’s scientific research agenda for…
Overview of the OHE Study on the Cost of Drug Development Presented
29 January 2013
OHE’s Jorge Mestre-Ferrandiz reviewed the results of OHE’s recent study on the R&D cost of developing a new drug at a seminar at University College London.…
Changes in Determining Medicines Pricing in France, Germany and the UK
24 January 2013
New requirements for health technology assessment in Europe have important implications for markets and for access to new medicines. At a recent conference, OHE’s Jorge Mestre-Ferrandiz…